⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Large Cap · Disruption threat: LOW
ResMed continues to embed AI and machine learning across its connected device ecosystem, particularly in sleep apnea management, remote patient monitoring, and its SaaS platform myAir/AirView, which leverage data from 200M+ connected devices. AI remains central to its competitive differentiation in chronic disease management, with ongoing investment in predictive analytics and care orchestration software.
ResMed is a large-cap medical device and SaaS company focused on sleep apnea, COPD, and respiratory care management. With an overall AI score of 68/100, the company sits in a solid mid-tier position, reflecting meaningful but still-maturing AI integration across its product and operational portfolio. Product AI Integration leads at 78/100, driven by tangible deployments including ML-based adaptive pressure algorithms in its AutoSet devices and AI-driven adherence coaching through the myAir app. R&D AI Investment scores 70/100, consistent with continued development of predictive analytics for patient outcomes across its 200M+ connected device network. Internal AI Use (62/100) and AI Infrastructure (58/100) trail, suggesting back-office automation and underlying data architecture have room to mature. Revenue from AI scores 55/100, indicating monetization of AI capabilities remains partially embedded within broader platform pricing rather than explicitly captured. ResMed's LOW disruption threat rating reflects strong structural advantages. Its proprietary device-to-cloud data flywheel, deep payer relationships, and clinical workflow integration create meaningful switching costs that limit vulnerability to AI-native competitors displacing its core business. The key opportunity lies in expanding AI-driven care orchestration within its SaaS platforms, AirView and Brightree, where automated resupply workflows and predictive intervention tools could accelerate recurring software revenue and margin expansion.
Full interactive analysis at RankVis.io